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BACKGROUND: Ticagrelor has superior efficacy to clopidogrel in the management 
of acute coronary syndromes but has not been assessed in patients undergoing 
percutaneous coronary intervention for stable coronary artery disease. We compared 
the pharmacodynamic effects of ticagrelor and clopidogrel in this stable population.
METHODS: One hundred eighty aspirin-treated stable coronary artery disease 
patients, who were planned to undergo elective percutaneous coronary intervention 
in a single center, were randomized 1:1:1 to either a standard clopidogrel regimen 
or 1 of 2 regimens of ticagrelor, either 90 mg (T90) or 60 mg twice daily (T60), both 
with a 180 mg loading dose. Cellular adenosine uptake was assessed, at the time of 
the procedure and pre- and postdose at 1 month, by adding adenosine 1 µmol/L to 
aliquots of anticoagulated whole blood and mixing with a stop solution at 0, 15, 30, 
and 60 seconds, then measuring residual plasma adenosine concentration by high-
performance liquid chromatography. Systemic plasma adenosine concentration and 
platelet reactivity were assessed at the same timepoints. High-sensitivity troponin T 
was measured pre- and 18 to 24 hours postpercutaneous coronary intervention.
RESULTS: One hundred seventy-four patients underwent an invasive procedure, of 
whom 162 received percutaneous coronary intervention (mean age 65 years, 18% 
female, 21% with diabetes mellitus). No effect on in vitro adenosine uptake was seen 
postdose at 1 month for either ticagrelor dose compared with clopidogrel (residual 
adenosine at 15 seconds, mean±SD: clopidogrel 0.274±0.101 µmol/L; T90 0.278±0.134 
µmol/L; T60 0.288±0.149 µmol/L; P=0.37). Similarly, no effect of ticagrelor on in vitro 
adenosine uptake was seen at other timepoints, nor was plasma adenosine concentration 
affected (all P>0.1). Both maintenance doses of ticagrelor achieved more potent and 
consistent platelet inhibition than clopidogrel (VerifyNow P2Y12 reaction units, 1 month, 
mean±SD: predose, T60: 62±47, T90: 40±38, clopidogrel 181±44; postdose, T60: 34±30, 
T90: 24±21, clopidogrel 159±57; all P<0.0001 for ticagrelor versus clopidogrel). High 
platelet reactivity was markedly less with both T60 and T90 compared with clopidogrel 
(VerifyNow P2Y12 reaction units>208, 1 month postdose: 0%, 0%, and 21%, respectively). 
Median (interquartile range) high-sensitivity troponin T increased 16.9 (6.5–46.9) ng/L for 
clopidogrel, 22.4 (5.5–53.8) ng/L for T60, and 17.7 (8.1–43.5) ng/L for T90 (P=0.95). There 
was a trend toward less dyspnea with T60 versus T90 (7.1% versus 19.0%; P=0.09).
CONCLUSIONS: Maintenance therapy with T60 or T90 had no detectable effect on 
cellular adenosine uptake at 1 month, nor was there any effect on systemic plasma 
adenosine levels. Both regimens of ticagrelor achieved greater and more consistent 
platelet inhibition than clopidogrel but did not appear to affect troponin release after 
percutaneous coronary intervention.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique 
identifier: NCT02327624.
© 2018 The Authors. Circulation is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution License, 
which permits use, distribution, and 
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Dual antiplatelet therapy with aspirin and an oral platelet P2Y12 receptor antagonist is the stan-dard therapy for patients undergoing percuta-
neous coronary intervention (PCI). Three oral platelet 
P2Y12 receptor antagonists are currently available: the 
thienopyridines clopidogrel and prasugrel, and the non-
thienopyridine, reversibly binding drug ticagrelor.1–4 In 
the absence of contraindications or concurrent oral an-
ticoagulant therapy, ticagrelor is recommended in pref-
erence to clopidogrel for patients with acute coronary 
syndromes, including those managed with PCI, but it 
has not been assessed in patients undergoing PCI for 
stable coronary artery disease (CAD).1–3 Similarly, pra-
sugrel is recommended in preference to clopidogrel 
for acute coronary syndrome patients managed with 
PCI, but is not licensed for use in stable CAD.1–3 Con-
sequently, aspirin and clopidogrel remain the predomi-
nant dual antiplatelet therapy strategy in stable CAD 
patients undergoing PCI.
Thienopyridines, such as clopidogrel, are prodrugs 
that require hepatic metabolism to generate active 
metabolites that bind irreversibly to the platelet P2Y12 
receptor, blocking the binding of ADP to this receptor.5 
The efficacy of clopidogrel is limited in some individuals 
due to poor efficiency of active metabolite formation 
and poor pharmacodynamic response has been associ-
ated with increased risk of stent thrombosis in clopido-
grel-treated patients.6,7
Ticagrelor is not a prodrug but does have an active 
metabolite, AR-C124910XX, that is equipotent to ti-
cagrelor and contributes approximately 30% of the to-
tal inhibitory effect.5,8,9 Ticagrelor achieves a consistent 
high level of platelet P2Y12 inhibition following a loading 
dose (although onset of action can be delayed in patients 
with ST-elevation myocardial infarction [MI]10,11), as well 
as during maintenance therapy with either 90 mg or 60 
mg BID in patients with prior MI.9 Ticagrelor and AR-
C124910XX also have weak inhibitory effects on cellu-
lar adenosine uptake via ENT-1 (equilibrative nucleoside 
transporter 1), although the clinical significance of this 
effect remains uncertain.12–14 The effects of ticagrelor 60 
mg BID on adenosine metabolism have not been pre-
viously reported. In the STEEL-PCI study (Study of Two 
Doses of Ticagrelor in PCI; NCT02327624), we assessed 
and compared the effects of ticagrelor and clopidogrel 
on cellular adenosine uptake, as well as platelet reactiv-
ity in stable CAD patients undergoing PCI.
METHODS
The data, analytic methods, and study materials will not be 
made available to other researchers for purposes of reproduc-
ing the results or replicating the procedure.
Study Design
One hundred eighty patients with stable CAD provided writ-
ten informed consent and were enrolled into the STEEL-PCI 
study, conducted at a single center (Northern General Hospital, 
Sheffield, United Kingdom). All patients had had previous cor-
onary angiography and were planned to undergo PCI. Other 
inclusion as well as exclusion criteria are shown in the online-
only Data Supplement. The study was performed according to 
a protocol approved by the National Research Ethics Service 
and regulatory authorities. Aspirin-treated patients who pro-
vided informed consent were randomized in a 1:1:1 fashion 
to receive open-label treatment with a 180 mg loading dose 
of ticagrelor at 2 hours pre-PCI, followed by either 60 mg BID 
or 90 mg BID for 1 month or a standard loading regimen of 
clopidogrel (600 mg at least 4 hours prior to procedure or 
maintenance therapy with 75 mg for at least 5 days), followed 
by 75 mg QD for 1 month (Figure 1). Blood samples were col-
lected at the time of PCI, either from a large antecubital vein 
using a 21-G needle and syringe with minimum use of tour-
niquet or from the arterial sheath, before the administration 
of heparin. Patients attended the morning after PCI for col-
lection of venous blood samples by venipuncture. At 1 month 
post-PCI, patients attended before the morning maintenance 
dose of study medication for further collection of venous blood 
samples. The maintenance dose was then administered and 
a further blood sample obtained 2 hours later. Patients were 
instructed to return unused study medication at their 1-month 
visit, and compliance was assessed by pill-counting. When 
indicated, patients were switched to open-label clopidogrel at 
the 1-month visit by administration of a loading dose 24 hours 
after the last dose of ticagrelor, as recommended.15,16 Staff of 
the Clinical Research Office of Sheffield Teaching Hospitals 
National Health Service Foundation Trust monitored the study, 
and a data monitoring committee periodically reviewed the 
conduct of the study and clinical outcomes.
Clinical Perspective
What Is New?
• Ticagrelor does not significantly impair adenosine 
uptake or increase circulating adenosine levels in 
patients with stable coronary artery disease.
• Ticagrelor 60 mg or 90 mg twice daily provides 
greater and more consistent platelet inhibition 
than clopidogrel in stable coronary artery disease 
patients undergoing elective percutaneous coro-
nary intervention. 
• More potent platelet P2Y12 inhibition did not mod-
ify troponin release related to percutaneous coro-
nary intervention.
What Are the Clinical Implications?
• Further studies of ticagrelor 60 mg twice daily are 
warranted in stable coronary artery disease patients 
undergoing percutaneous coronary intervention.
• Asymptomatic troponin release may not be a suit-
able end point for assessing the impact of greater 
platelet inhibition in stable coronary artery dis-
ease patients undergoing percutaneous coronary 
intervention.
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Adenosine Uptake and Plasma Adenosine 
Level
For adenosine reuptake measurements, blood was col-
lected into a standard ethylenediaminetetraacetic acid tube 
and then aliquots pipetted into tubes containing adenosine 
(final concentration: 1 µmol/L). Uptake of adenosine was 
halted by the addition of a cold pharmacological stop solu-
tion (2 parts blood:1 part stop solution) at 0, 15, 30, or 60 
seconds after mixing blood with the adenosine. The stop 
solution was composed of dipyridamole 40 µmol/L, diso-
dium ethylenediaminetetraacetic acid 13.2 mmol/L, erythro-
9-(2-hydroxy-3-nonyl)adenine 50 µmol/L, α,β-methylene 
adenosine 5’-diphosphate 200 µmol/L, iodotubercidin 50 
µmol/L, and p-nitrobenzylthioinosine 40 µmol/L in 0.9% 
wt/vol sodium chloride. Adenosine concentration was mea-
sured using high-performance liquid chromatography (see 
the online-only Data Supplement).
Samples for plasma adenosine concentration measure-
ment were collected into S-Monovette tubes containing the 
stop solution and immediately placed on ice before centrifu-
gation at 1500g. Adenosine concentration was then mea-
sured as described above.
VerifyNow P2Y12 Assay
Whole blood was collected into 2-mL Greiner Bio-One citrate 
tubes and gently mixed before analysis after 20 minutes 
using the VerifyNow P2Y12 assay (Accumetrics Inc, USA). 
P2Y12 reaction units (PRU) and VerifyNow percentage inhi-
bition (estimated using the Base channel result as 100% 
response) were recorded.
Light Transmittance Aggregometry
Light transmission aggregometry (LTA) was performed 
using a PAP8 aggregometer (Biodata; Horsham, USA) with 
ADP 20 μmol/L as the agonist. Maximum percentage LTA 
responses were recorded.
High-Sensitivity Troponin T
High-sensitivity troponin T was determined in serum samples 
(Elecsys assay, Roche, on a Cobas E602 analyser) before PCI 
and the morning after PCI.
Pharmacokinetic Analysis
Plasma derived from blood anticoagulated with lithium heparin 
was stored at –80°C prior to analysis. Plasma concentrations 
of ticagrelor and AR-C124910XX were determined using liq-
uid chromatography with tandem mass spectrometry by York 
Bioanalytical Solutions (Upper Poppleton, United Kingdom).17
Genetic Analysis
DNA was extracted from whole blood and analyzed for rel-
evant genetic variants of CYP2C19, CY3A43, UGT2B7, and 
SLC01B1 (see the online-only Data Supplement).
Sample Size and Statistical Analysis
The primary end point of the study was in vitro adenosine uptake 
postmaintenance dose at 1 month, measured as residual ade-
nosine concentration at 15 seconds after ex vivo addition of ade-
nosine. The sample size was based on (1) our preliminary in vitro 
Figure 1. Study design. 
Hs indicates high-sensitivity; LD, loading dose; LTA (ADP), light transmittance aggregometry with ADP; PCI, percutaneous coronary intervention; and R, randomization.
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studies of adenosine uptake indicating 15 seconds as the optimal 
time for assessing residual adenosine concentration, and previ-
ous data indicating an estimated mean (±SD) residual adenosine 
concentration at 15 seconds postmixing in the adenosine uptake 
assay of 0.80±0.051 µmol/L for the ticagrelor 90 mg group and 
0.45±0.068 µmol/L for clopidogrel18; and (2) the assumption that 
the effects of ticagrelor 60 mg would yield levels between those 
with ticagrelor 90 mg and clopidogrel. Data on 42 patients per 
group were required in each group to provide >90% power to 
detect a 0.05 µmol/L higher mean residual adenosine level in the 
ticagrelor 60 mg group compared with the clopidogrel group, 
with a significance threshold of 0.05 and assuming a common 
SD of 0.06 µmol/L, and >99% power to detect a similar differ-
ence between the ticagrelor 90 mg and clopidogrel groups to 
that previously reported. Sixty patients were, therefore, required 
in each group to allow for 30% dropout or sample failure at 1 
month. Secondary endpoints were plasma adenosine concen-
tration, platelet function measurements, and the PCI-induced 
troponin release (determined as increase from pre-PCI to post-
PCI). Based on our previous work,8,9 the proposed sample size 
provided >90% power to detect expected differences in platelet 
aggregation, assessed by either VerifyNow P2Y12 assay or LTA, 
between ticagrelor and clopidogrel, with a significance threshold 
of 0.01 (to allow for multiple testing), allowing for 30% dropout 
or sample failure at 1 month.
Data were analyzed using SAS version 9.3 (SAS Institute, 
USA) and expressed as mean and SD for normally distributed 
data or median and interquartile range for nonparametric 
data. Continuous data were compared using the Kruskal-
Wallis test, where appropriate using the Mann-Whitney test 
for pairwise comparisons, as indicated in Results. Categorical 
variables were compared using the chi-square test or Fisher 
exact test, as indicated in Results. High platelet reactivity was 
defined as VerifyNow PRU >208 or LTA response >59%.9 MI 
was defined according to the Third Universal Definition.19 
Bleeding events were defined according to the PLATO study 
(Platelet Inhibition and Patient Outcomes) criteria.20
RESULTS
Study Population
One hundred eighty patients were recruited to the study 
(Figure 2). Sixty patients in the clopidogrel group, 56 in 
the ticagrelor 60 mg BID group, and 58 in the ticagre-
lor 90 mg BID group underwent an invasive procedure. 
Some patients did not proceed to PCI for several rea-
sons, including significant disease progression requiring 
surgical management or nonflow-limiting coronary ste-
nosis on updated angiography. One hundred fifty-five 
patients completed the study period of maintenance 
therapy with clopidogrel 75 mg QD (n=53), ticagre-
lor 60 mg BID (n=54), or ticagrelor 90 mg BID (n=48). 
Figure 2. CONSORT study (Consolidated Standards of Reporting Trials) flow diagram. 
Number of patients in each of the 3 treatment groups (clopidogrel, ticagrelor 60 mg BID, and ticagrelor 90 mg BID) at each stage of the study. CAD indicates 
coronary artery disease; PCI, percutaneous coronary intervention; and R, randomization.
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One patient in the ticagrelor 60 mg BID group was 
subsequently found to have been taking an excluded 
medication (a strong CYP3A [cytochrome P450, family 
3, subfamily A] inducer), and was excluded from the 
main analysis; however, their results are included in the 
online-only Data Supplement. The demographic char-
acteristics, cardiovascular risk factors, and concomitant 
medications were well matched between the groups at 
randomization and subsequent timepoints, as were the 
procedural characteristics for those proceeding with 
PCI (Table 1 and Tables I and II in the online-only Data 
Supplement). At the time of their procedure, 100% pa-
tients were receiving aspirin 75 mg daily and continued 
on this for the duration of the study.
Adenosine Uptake and Plasma 
Adenosine Level
No effect on in vitro adenosine uptake was seen with 
a ticagrelor loading dose or the 90 mg or 60 mg BID 
maintenance doses compared to clopidogrel at the 
time of PCI or at 1 month (Figure 3 and Figure I in the 
online-only Data Supplement). Similarly, there was no 
impact of ticagrelor at any time point on plasma ad-
enosine level (Figure 4).
VerifyNow P2Y12 Assay and Light 
Transmittance Aggregometry
Ticagrelor 180 mg loading dose achieved greater and 
more consistent platelet inhibition than clopidogrel at 
the time of PCI when assessed by the VerifyNow P2Y12 
assay (Figure 5A and 5B). Both maintenance doses of 
ticagrelor achieved greater and more consistent plate-
let inhibition than clopidogrel 75 mg daily at 1 month 
(Figure  5C and 5D). The mean (±SD) predose PRU 
values were 62±47 versus 40±38 (P<0.01) for the 60 
mg versus 90 mg ticagrelor doses, and postdose val-
ues were 34±30 versus 24±21 (P=0.09), respectively; 
corresponding PRU values for clopidogrel-treated pa-
tients were 181±44 predose and 159±57 postdose (all 
P<0.0001 versus both ticagrelor groups). The mean LTA 
responses were also significantly lower in the ticagrelor 
groups compared with the clopidogrel group, both at 
the time of PCI and at 1 month (Figure 6).
High platelet reactivity, as assessed by the VerifyNow 
P2Y12 assay, was seen infrequently in the ticagrelor 
group (n=1) at the time of PCI (Table 2). This patient 
also had high platelet reactivity when assessed by LTA. 
No patients in the ticagrelor 90 mg BID group had high 
platelet reactivity (PRU>208) at 1 month compared to 1 
patient in the ticagrelor 60 mg BID group. This patient 
had a PRU value of 232 at 1 month predose and 39 
postdose, with a PRU of 1 at the time of PCI; their drug 
compliance at 1 month was calculated at 100%. High 
platelet reactivity was more common in the clopidogrel 
group at all the timepoints compared to both ticagrelor 
groups (Table 2).
There were a small number of patients with high 
platelet reactivity in the ticagrelor groups (<15%) ac-
cording to LTA responses compared to greater propor-
tions in the clopidogrel group (>30%) at each timepoint 
(Figure 6B and Table 2).
Efficacy, Safety, and Tolerability
There were no MIs, strokes, or cardiac deaths in any of 
the groups at 30 days. There was only 1 death, which 
occurred as a result of sepsis following mesenteric infarc-
tion that did not appear to be related to the PCI proce-
dure. There was no effect of the higher levels of plate-
let inhibition with ticagrelor on PCI-induced increase in 
high-sensitivity troponin T: median (interquartile range) 
increases the morning after PCI were 16.9 (6.5–46.9) 
ng/L for the clopidogrel group, 22.4 (5.5–53.8) ng/L for 
the ticagrelor 60 mg group, and 17.7 (8.1–43.5) ng/L for 
the ticagrelor 90 mg group (P=0.95, Kruskal-Wallis test).
The tolerability of the ticagrelor 60 mg BID dose ap-
peared slightly better than the 90 mg BID dose due to 
less frequent dyspnea events in the 60 mg group (7.1% 
versus 19.0%; P=0.09) (Table III in the online-only Data 
Supplement). Two patients (3.6%) in the ticagrelor 60 
mg group and 3 patients (5.2%) in the ticagrelor 90 
mg group stopped study medication prematurely due 
to adverse effects. There was no reported dyspnea in 
the clopidogrel group, and no patients stopped clopi-
dogrel prematurely due to adverse effects. There were 
no PLATO-defined major or minor bleeds and no major 
adverse cardiac events or stent thrombosis events in 
any of the treatment groups.
Pharmacokinetics
The mean plasma levels of ticagrelor and AR-
C124910XX following ticagrelor 180 mg loading dose 
were 1109±549 and 223±121 ng/mL, respectively (Fig-
ure IIA in the online-only Data Supplement). After 1 
month maintenance therapy with either ticagrelor 60 
mg or ticagrelor 90 mg BID, predose mean levels of 
ticagrelor were 278±217 and 365±189 ng/mL, respec-
tively, and predose mean levels of AR-C124910XX were 
97±55 and 127±73 ng/mL, respectively. Postdose mean 
levels of ticagrelor were 510±281 and 776±347 ng/mL, 
and mean levels of AR-C124910XX were 135±69 and 
199±96 ng/mL, respectively (Figure IIB in the online-
only Data Supplement).
Genetic Analysis
The ticagrelor loading dose and both ticagrelor main-
tenance doses achieved greater platelet inhibition than 
clopidogrel in those who either did or did not carry 
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Table 1. Demographic and Procedural Characteristics and Medications for Patients Proceeding With 
Percutaneous Coronary Intervention
 Clopidogrel Ticagrelor 60 mg Ticagrelor 90 mg
 n=57 n=54 n=51
Age, y, mean (SD) 64.6 (8.5) 66.9 (8.6)  66.0 (7.73)
Male sex, n (%) 44 (77) 46 (85) 42 (82)
Body weight, kg, median (IQR) 85.5 (77–102) 88.0 (73–97) 85.0 (80–98)
Body mass index, mean (SD) 30.3 (5.7) 28.8 (3.7) 30.0 (4.6)
Race, n (%)
  White 56 (98) 53 (98) 49 (96)
  Black 1 (2) 0 (0) 1 (2)
  Asian 0 (0) 1 (2) 1 (12)
Cardiovascular risk factors, n (%)
  Current smoker 7 (12) 6 (11) 6 (12)
  Hypertension 39 (68) 37 (69) 34 (67)
  Dyslipidemia 51 (90) 47 (87) 49 (96)
  Diabetes mellitus 12 (21) 11 (20) 12 (24)
Medical history, n (%)
  Myocardial infarction 9 (16) 9 (17) 4 (8)
  PCI 5 (9) 5 (9) 7 (14)
  Coronary artery bypass graft 3 (5) 3 (6) 1 (2)
  Cardiac failure 5 (9) 5 (9) 2 (4)
  Transient ischemic attack 3 (5.3) 3 (5.6) 2 (4)
  Nonhemorrhagic stroke 1 (1.8) 1 (1.9) 2 (4)
  Peripheral arterial disease  6 (11) 5 (9) 3 (6)
  COPD 5 (9)  5 (9) 3 (6)
Concomitant medication, n (%)
  Aspirin 75 mg daily 57 (100) 54 (100) 51 (100)
  β-Blocker 50 (88) 40 (74) 33 (65)
  ACE inhibitor 15 (26) 18 (33) 13 (26)
  Statin 51 (90) 48 (89) 44 (86)
CYP2C19 LOF carrier, n (%) 18 (32) 20 (37) 12 (24)
Procedural characteristics
  Number of vessels treated, mean (SD) 1.2 (0.5) 1.2 (0.4) 1.1 (0.6)
  Number of lesions treated, mean (SD) 1.5 (0.8) 1.5 (0.7) 1.4 (0.7)
  Total stent length, mm, mean (SD) 39 (27) 39 (23) 37 (24)
  Minimum stent diameter, mm, mean (SD) 3.0 (0.6) 3.0 (0.5) 3.0 (0.5)
  Bifurcation treated, n (%) 1 (2) 4 (7) 2 (4)
  Left main stem treated, n (%) 1 (2) 3 (6) 2 (4)
  Arterial access, n (%)    
   Radial 45 (79) 41 (76) 38 (75)
   Femoral 10 (18) 13 (24) 12 (24)
   Radial-to-femoral 2 (4) 0 (0) 0 (0)
   Brachial 0 (0) 0 (0) 1 (2)
Groups were compared using Kruskal-Wallis or chi-square tests, as appropriate: all P values >0.1 except 
for β-blockers (P=0.02). ACE indicates angiotensin-converting enzyme; COPD: chronic obstructive pulmonary 
disease; CYP2C19 LOF, loss-of-function allele carrier for cytochrome P450 2C19; IQR, interquartile range; and 
PCI, percutaneous coronary intervention.
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CYP2C19 loss-of-function alleles (Tables IV and V in the 
online-only Data Supplement). The other genetic vari-
ants studied did not significantly influence the phar-
macodynamic and pharmacokinetic results (Tables VI 
through XI in the online-only Data Supplement).
DISCUSSION
In this study, we compared the pharmacodynamic ef-
fects of ticagrelor and clopidogrel, obtaining data on 
the 60 mg BID dose of ticagrelor for the first time in 
stable CAD patients undergoing PCI and collecting 
preliminary efficacy, safety, and tolerability data on 
the 2 doses of ticagrelor in this setting. Consistent 
with previous comparisons of the ticagrelor 180 mg 
loading dose and 90 mg twice-daily maintenance dose 
with standard regimens of clopidogrel in other clini-
cal settings, we confirmed that the ticagrelor loading 
dose and maintenance doses achieved greater and 
more consistent levels of platelet inhibition compared 
to standard regimens of clopidogrel in stable CAD pa-
tients at the time of, and 1 month after, PCI. Of note, 
we show that the ticagrelor 60 mg twice-daily main-
tenance dose provides much more consistent platelet 
inhibition than clopidogrel, even in those with normal 
CYP2C19 activity as predicted by CYP2C19 genotyp-
ing. Our data are broadly consistent with previously 
reported data on ticagrelor 90 mg and 60 mg twice 
daily in patients with prior MI.9,21 Our finding of sig-
nificant difference in predose platelet reactivity dur-
Figure 3. Whole blood in vitro adenosine uptake. 
Residual adenosine levels at 15 seconds after mixing adenosine 1 μmol/L with blood samples obtained (A) at the time of percutaneous coronary intervention fol-
lowing a standard loading regimen of clopidogrel (n=54) or 180 mg loading dose of ticagrelor (n=50 and 54 for 60 mg and 90 mg groups, respectively), and (B) 
after 1 month of treatment, premaintenance dose and postmaintenance dose for each of the 3 treatment groups (clopidogrel 75 mg QD: n=45; ticagrelor 60 mg 
BID: n=46; and ticagrelor 90 mg BID; n=43 and 45). Horizontal bars indicate mean±SD. P values determined using 3-group comparison with Kruskal-Wallis test.
Figure 4. Plasma adenosine concentration. 
Plasma adenosine levels (A) at the time of percutaneous coronary intervention following a standard loading regimen of clopidogrel (n=56) or 180 mg loading dose 
of ticagrelor (n=50 and 54 for 60 mg and 90 mg groups, respectively) and (B) after 1 month of treatment, premaintenance dose and postmaintenance dose for 
each of the 3 treatment groups (clopidogrel 75 mg QD: n=45; ticagrelor 60 mg BID: n=46; and ticagrelor 90 mg BID: n=43). Horizontal bars show mean±SD. P 
values determined using 3-group comparison with Kruskal-Wallis test.
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ing maintenance therapy in the 2 ticagrelor groups, in 
contrast to lack of significance of this comparison in 
the PEGASUS-TIMI 54 platelet function substudy (Pre-
vention of Cardiovascular Events in Patients With Prior 
Heart Attack Using Ticagrelor Compared to Placebo 
on a Background of Aspirin-Thrombolysis in Myocar-
dial Infarction 54),9 likely reflects small sample sizes in 
both studies, limiting the power to detect such a dif-
ference. Dyspnea was more frequent in the ticagrelor 
groups, and this is a well-characterized adverse effect 
of ticagrelor that is usually mild or moderate in sever-
ity, as confirmed here.22–24 The lower rates of dyspnea 
in the ticagrelor 60 mg group, combined with the reli-
able P2Y12 inhibition, as also previously demonstrated 
in the PEGASUS-TIMI 54 study,9,24 favor this dose for 
further exploration in clinical outcomes studies.
Contrary to some previous published studies,18,25 
we found no evidence of any effect of the ticagrelor 
regimens on cellular adenosine uptake or plasma ad-
enosine concentration. The reasons for this are unclear 
since our data show clearly that the assay assessed ad-
enosine uptake over 1 minute in whole blood samples, 
with the expected baseline levels of adenosine after 
in vitro addition of 1 µmol/L (indicating efficacy of the 
stop solution in preventing further adenosine uptake) 
and almost complete adenosine uptake at 1 minute 
(indicating efficacy of the stop solution in preventing 
adenosine generation). Our stop solution for adenos-
ine metabolism included additional inhibitors to those 
used by Bonello et al,18 including p-nitrobenzylthio-
inosine as an additional inhibitor of adenosine uptake 
and iodotubercidin as a potent adenosine kinase in-
hibitor, and therefore may have been more effective. In 
agreement with our findings, a recent study in healthy 
volunteers found no impact of ticagrelor on plasma 
adenosine level.26 Furthermore, using the same meth-
odology, we found no impact of ticagrelor on plasma 
adenosine concentration in acute coronary syndrome 
Figure 5. VerifyNow P2Y12 Assay Results. 
Individual VerifyNow P2Y12 assay results expressed as (A and C) P2Y12 reaction units (PRU) and (B and D) VerifyNow percentage inhibition, (A and B) at the time 
of percutaneous coronary intervention following a standard loading regimen of clopidogrel (n=59) or 180 mg loading dose of ticagrelor (n=54 and 58 for 60 mg 
and 90 mg groups, respectively) and (C and D) after 1 month of treatment, premaintenance dose and postmaintenance dose for each of the 3 treatment groups 
(clopidogrel 75 mg QD: n=52; ticagrelor 60 mg BID: n=52; and ticagrelor 90 mg BID: n=48). The dashed lines indicate a level of 208 PRU as a threshold for high 
platelet reactivity. Horizontal bars indicate mean±SD. P values determined using 3-group comparison with Kruskal-Wallis test with pairwise comparisons using 
Mann-Whitney test; * P<0.01; *** P<0.0001.
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patients awaiting coronary artery bypass graft surgery, 
suggesting that the nature of the patient population in 
our current study was not a determinant of the find-
ings.27 In vitro studies predict little effect of ticagrelor 
on adenosine uptake at therapeutic concentrations 
due to high levels of plasma protein binding that limit 
the free ticagrelor available to bind to ENT-1.14,28 On 
the other hand, an effect of ticagrelor on adenosine 
uptake is more clearly seen at approximately therapeu-
tic concentrations in the absence of plasma proteins.29 
Since ticagrelor has been shown to induce a leftward 
shift in the dose-response curves for intravenous ad-
enosine in studies of coronary blood flow responses 
and dyspnea severity, it remains likely that ticagrelor 
has an impact on the kinetics of adenosine uptake in 
vivo at the tissue level, such as in myocardium, that is 
not detected by the currently available blood assays, 
and more work is required to assess this.13,30
There were substantial numbers of patients with 
asymptomatic rises in troponin after PCI, but no evi-
dence that ticagrelor was more effective than clopi-
dogrel in attenuating troponin release, suggesting 
that the extent of myocardial injury induced by PCI is 
not usually sensitive to levels of platelet P2Y12 inhibi-
tion in a low-risk population. This observation is con-
sistent with a previously reported small elective PCI 
study,31 but contrasts with another small study that 
demonstrated a reduced rate of MI with ticagrelor 
compared to clopidogrel.32 Larger clinical outcomes 
studies are in progress that will provide more de-
finitive data on this comparison (NCT02617290 and 
NCT02548611).
Figure 6. ADP-induced platelet aggregation determined by LTA. 
Individual results for the platelet aggregation measured by light transmittance aggregometry in response to ADP 20 μmol/L (A) at the time of percutaneous coro-
nary intervention  following a standard loading regimen of clopidogrel (n=59) or 180 mg loading dose of ticagrelor (n=54 and 55 for 60 mg and 90 mg groups, 
respectively) and (B) after 1 month, premaintenance dose and postmaintenance dose for each of the 3 treatment groups (clopidogrel 75 mg QD: n=50 and 51; 
ticagrelor 60 mg BID: n=51 and 52; and ticagrelor 90 mg BID: n=45 and 48). The dashed lines indicate a level of 59% as a threshold value for high platelet reactiv-
ity. Horizontal bars indicate mean±SD. P values determined using 3-group comparison with Kruskal-Wallis test with pairwise comparisons using Mann-Whitney 
test; *** P<0.0001. LTA indicates light transmittance aggregometry; and max, maximum.
Table 2. Proportions of Patients With High Platelet Reactivity According to Predefined Threshold Values
Threshold of High 
Platelet Reactivity
Clopidogrel Ticagrelor 60 mg P Value Ticagrelor 90 mg P Value
n N (%) n N (%)
Clopidogrel 
vs. Ticagrelor 
60 mg n N (%)
Clopidogrel 
vs. Ticagrelor 
90 mg
VerifyNow PRU >208
  Postloading dose 59 18 (31) 53 1 (2) <0.0001 57 0 (0) <0.0001
  1 month, predose 50 14 (28) 51 1 (2) <0.0001 45 0 (0) <0.0001
  1 month, postdose 52 11 (21) 52 0 (0) <0.0001 48 0 (0) <0.0001
LTA 20 μM ADP >59%
  Postloading dose 59 18 (31) 54 4 (7) 0.002 56 1 (2) <0.0001
  1 month, predose 50 30 (60) 51 6 (12) <0.0001 45 2 (4) <0.0001
  1 month, postdose 53 22 (42) 52 2 (4) <0.0001 48 1 (2) <0.0001
N indicates number of patients with values above the given threshold value. % = (N/n) ×100; n = number of patients with available 
data in each treatment group. Clopidogrel and each ticagrelor group are compared using the Fisher exact test. All comparisons between 
the ticagrelor groups: P>0.1. LTA indicates light transmittance aggregometry; and PRU, P2Y12 reaction unit.
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This study was limited by a small sample size for as-
sessing efficacy, safety, and tolerability, and a larger study 
is required to establish the benefits and risks of ticagrelor 
in stable CAD patients undergoing PCI. Our study sim-
ply provides pilot data for planning such a study. Only 
the impacts of ticagrelor on adenosine uptake in whole 
blood and circulating adenosine levels were assessed, 
not the impact of ticagrelor on tissue-level adenosine 
metabolism. The study was also not well powered for 
comparing the pharmacodynamic effects of the 2 main-
tenance doses of ticagrelor, although some significance 
was seen in predose levels of platelet reactivity suggest-
ing that the 90 mg BID dose may have slightly greater 
consistency of effect than the 60 mg BID dose.
In conclusion, ticagrelor 60 mg and 90 mg BID regimens 
both achieved greater and more consistent platelet inhi-
bition than standard clopidogrel therapy, but had no de-
tectable impact on cellular adenosine uptake or circulating 
plasma adenosine concentration in stable CAD patients 
undergoing PCI. Further work is warranted to characterize 
the efficacy and safety of ticagrelor in this clinical setting.
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